Disease-modifying anti-rheumatic drugs (DMARDs) reduce tissue destruction by suppressing the auto-immune attack on the joints.
Serum acute phase proteins (ACP) are measured monthly to assess the effectiveness of DMARDs such as:
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page